Cargando…
Antithrombin and hypercoagulability in sepsis: insights from thrombelastography?
Antithrombin (AT) has been used for over 25 years to successfully treat disseminated intravascular coagulation (DIC). A four-day AT therapy in patients with DIC in the KyberSept trial has been related to a clear survival benefit in patients not receiving concomitant heparin. Gonano and coworkers per...
Autores principales: | Hoffmann, Johannes N, Schick, Kerstin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151912/ https://www.ncbi.nlm.nih.gov/pubmed/17331267 http://dx.doi.org/10.1186/cc5156 |
Ejemplares similares
-
Thrombelastography and sepsis
por: Puana, Rudolph, et al.
Publicado: (2007) -
Identification of hypercoagulability with thrombelastography in patients with hip fracture receiving thromboprophylaxis
por: You, Daniel, et al.
Publicado: (2021) -
Antithrombin in sepsis revisited
por: Levi, Marcel
Publicado: (2005) -
Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis
por: Gonano, Christopher, et al.
Publicado: (2006) -
Hypercoagulability as Measured by Thrombelastography May Be Associated with the Size of Acute Ischemic Infarct—A Pilot Study
por: Wiśniewski, Adam, et al.
Publicado: (2021)